new molecules and indications for glp 1 medicines The expanding landscape of GLP-1 Frontiers | The immunomodulatory effects

A main way GLP-1s lead to weight loss is by slowing down the rate at which food leaves the stomach, making you feel fuller for longer and less hungry throughout the day

Amgens Phase 2 trial of MariTide showed remarkable efficacy: non-diabetic patients lost ~20% of body weight in 52 weeks (vs just 2.6% for placebo)

In practice, these men might use PT-141 alone or in combination with a PDE5i to achieve a satisfactory result

Listeners consistently praise the show: This podcast is informative and wellrounded Ana Reisdorf draws from her own experience with GLP1 offers scientifically factual and rational information. You can find the podcast on any platform where you listen to podcasts or by visiting the GLP-1 Hub podcast page

There was no head-to-head trial directly comparing these antidiabetic drug classes